Malloy Katherine M, Davis George A
University of Kentucky Hospital, Department of Pharmacy, 800 Rose Street, Lexington, KY 40536-2093, USA.
Orthopedics. 2009 Jul;32(7):499. doi: 10.3928/01477447-20090527-18.
Vancomycin has been used extensively for the treatment of Gram-positive bacterial infections, especially in cases of methicillin-resistant Staphylococcus aureus (MRSA). Despite long-term use, many uncertainties have remained regarding appropriate dosing, monitoring, and toxicity risks. In January 2009, a committee representing the American Society of Health-System Pharmacists (ASHP), the Infectious Diseases Society of America (IDSA), and the Society of Infectious Diseases Pharmacists (SIDP) released recommendations for vancomycin monitoring. As osteomyelitis patients are frequent recipients of vancomycin, this article provides a summary of the recommendations in reference to loading and maintenance doses, trough concentration monitoring, frequency of monitoring, and risk of toxicities.
万古霉素已被广泛用于治疗革兰氏阳性菌感染，尤其是耐甲氧西林金黄色葡萄球菌（MRSA）感染的病例。尽管长期使用，但在合适的剂量、监测及毒性风险方面仍存在许多不确定性。2009年1月，一个代表美国卫生系统药师协会（ASHP）、美国传染病学会（IDSA）和传染病药师协会（SIDP）的委员会发布了万古霉素监测的建议。由于骨髓炎患者经常接受万古霉素治疗，本文总结了关于负荷剂量和维持剂量、谷浓度监测、监测频率及毒性风险的建议。
